NCT00377052View on ClinicalTrials.gov

Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 16, 2007

Primary Completion Date

April 21, 2009

Study Completion Date

June 21, 2011

Conditions
Lymphoma
Interventions
DRUG

bortezomib

1.0 mg/m2 IV; injection bolus (3-5 sec) Twice weekly x 2 weeks every three weeks

DRUG

gemcitabine hydrochloride

1000 mg/m2 IV; injection 30 minute infusion Once weekly x 2 weeks every three weeks

Trial Locations (11)

T6G 1Z2

Cross Cancer Institute, Edmonton

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

R3E 0V9

CancerCare Manitoba, Winnipeg

B3H 1V7

QEII Health Sciences Center, Halifax

QEII, CCR, Hematology Research, Halifax

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

N6A 4L6

London Regional Cancer Program, London

M4N 3M5

Odette Cancer Centre, Toronto

M5G 2M9

Univ. Health Network-Princess Margaret Hospital, Toronto

H2W 1S6

McGill University - Dept. Oncology, Montreal

S7N 4H4

Saskatoon Cancer Centre, Saskatoon

Sponsors
All Listed Sponsors
lead

NCIC Clinical Trials Group

NETWORK